Ryan T Wallace

Dr. Ryan T Wallace

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Vision
Verified
Journal Article
Open access
PDF file
APAyesha Patil
Ayesha Patil
CSCole Swiston
Cole Swiston
RWRyan T Wallace
Ryan T Wallace
CPChase Paulson
Chase Paulson
MCMatthew E. Conley
Matthew E. Conley
BWBarbara M. Wirostko
Barbara M. Wirostko
(1) Background: Exfoliation syndrome (XFS) is a common cause of secondary open angle glaucoma. In 1971, Faulkner et al. estimated the prevalence of XFS among 50 Navajo Nation residents as 38%. Given that XFS can cause irreversible blindness secondary to glaucoma (XFG), this study aims to identify the current prevalence of XFS among Navajo Nation residents within the Four Corners region of the U.S. (2) Methods: A retrospective chart review was conducted from 2016 to 2021 for patients aged 18 and older. All patients with XFS or XFG diagnosed by slit lamp exam were identified through chart review. (3) Results: Of the 1152 patient charts available for review, eight patients (11 eyes) were diagnosed with XFS with three patients (4 eyes) demonstrating concomitant XFG. Within this XFS population, 50% of the patients identified as male, with a mean age of 73 years. The overall prevalence of XFS was 0.7% and the overall prevalence of XFG was found to be 0.26%. The rate of XFG among patients with XFS was 37.5%. (4) Conclusion: Compared to Faulkner’s study of Navajo Nation residents in 1971, our findings show a considerably lower prevalence of XFS at 0.7%. We present the largest study to date of XFS among this population.

25 January 2023 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
AAAzraa Ayesha
Azraa Ayesha
RWRyan T Wallace
Ryan T Wallace
AMAnthony P. Mai
Anthony P. Mai
RSRachel G. Simpson
Rachel G. Simpson
CCCraig J. Chaya
Craig J. Chaya
To report the observation of iris atrophy with the use of Dexycu in cataract surgery and describe a possible mechanism for this complication. Between 2020 and 2021, 2 patients underwent cataract surgery procedures with the use of Dexycu and experienced iris atrophy. The first case of iris atrophy was discovered by 6-month follow-up and the second case by 2-month follow-up. The timing and nature of this complication possibly represent more than steroid-induced hypopigmentation. This publication adds further evidence of iris atrophy and a proposed mechanism associated with the use of Dexycu. Surgeons should be aware of this complication, especially when operating on eyes with dark irides.

CJCatherine Johnson
Catherine Johnson
MJMichael Seth Jensen
Michael Seth Jensen
JMJohn Musser
John Musser
NKNeil Kelkar
Neil Kelkar
KEKevin Eid
Kevin Eid
CCCraig J. Chaya
Craig J. Chaya
Background: In this study, we compare the 12-month results of eyes that underwent ab externo, open-conjunctival XEN45 gel stent placement with mitomycin C (MMC) with and without the intraoperative addition of Ologen collagen matrix (XEN45 and XEN45 + Ologen groups, respectively). Methods: Intraocular pressure (IOP) measurements were recorded postoperation at 1 month, 3 months, 6 months, and 9 months, and 12 months, and IOP reduction, reduction in number of IOP-lowering medications, and success rate were compared between XEN45 and XEN45 + Ologen groups. A complete success was defined as a ≥20% drop from baseline IOP at 12 months without the use of medications and without any of the following: an additional procedure (e.g., needling), a recorded IOP ≥ 21 mm Hg at two consecutive visits, or the occurrence of catastrophic events (e.g., no light perception (NLP)). A qualified success was defined as an IOP reduction of ≥20% from baseline with the use of medications. We included 145 eyes with at least 1 month of follow-up data, 46 in the XEN45 group and 99 in the XEN45 + Ologen group. Of these, 113 eyes had 12 months of follow-up data comprising 41 XEN45 eyes and 72 XEN45 + Ologen eyes. Results: There were no significant differences in the IOP change from baseline between XEN45 and XEN45 + Ologen groups except at the 3-month postop timepoint (p < 0.05). At the 12-month follow-up, 41.5% (17/41) of XEN45 eyes and 52.8% (38/72) of XEN45 + Ologen eyes met complete or qualified success criteria. Conclusions: No significant differences in success rate and decrease in the number of IOP-lowering medications from baseline were identified between XEN45 and XEN45 + Ologen groups.

11 July 2022 in Vision
Verified
Journal Article
Open access
PDF file
RWRyan T Wallace
Ryan T Wallace
MMMichael Murri
Michael Murri
LMLori L McCoy
Lori L McCoy
EPEsteban Peralta
Esteban Peralta
JPJeff H. Pettey
Jeff H. Pettey
CCCraig J. Chaya
Craig J. Chaya
The Navajo Nation is the largest Native American reservation by area and citizenship. The study sought to provide the first large-scale examination of ocular pathology within this population. A retrospective review of all Navajo patients seen at Moran Eye Center Navajo Nation Outreach Clinics from 2013 to 2021 for demographics, visual acuity, refractive, and eye pressure data was undergone. Further variables included comorbidity and eye diagnoses among patients at these clinics. Results: First-time patient visits totaled 2251 from 2013 to 2021. The median age was 53 (range, 18 to 92), and clinics had a predominance of female patients (1387:864). Among patients presenting without glasses, 20.67% (198/958), 9.71% (93/958), and 3.13% (30/958) had mild visual impairment (VI), moderate to severe VI, and blindness, respectively. Cataracts were the most common cause of blindness in these patients (40%, 12/30) and the need for glasses was the second most common cause (33%, 10/30). From 2016 to 2021, 17.71% (48/271) of diabetic patients were diagnosed with diabetic retinopathy (DR). Within the subset of Navajo patients that presented without any correction, 73% of bilateral blindness was preventable via glasses prescription or cataract surgery. This study comments on questions of equitable care for Navajo patients.

23 October 2026 in American Journal of Ophthalmology
Verified
Journal Article
Open access
SKSujin Kang
Sujin Kang
RWRyan T Wallace
Ryan T Wallace
SGSteven J. Gedde
Steven J. Gedde
CBCaroline M. Borie
Caroline M. Borie
ZAZubair A. Ansari
Zubair A. Ansari
DTDespoina Theotoka
Despoina Theotoka
To characterize the clinical features, surgical management, and outcomes of Morgagnian cataracts. Retrospective clinical cohort study. Fifty eyes of 50 adults diagnosed with Morgagnian cataracts at a tertiary academic referral center in the United States from October 2015 through August 2026. Medical records were reviewed for demographic characteristics, ocular findings, imaging, surgical management, intraoperative complications, intraocular lens (IOL) fixation, postoperative complications, best-corrected visual acuity (BCVA), and intraocular pressure (IOP). Surgical management, intraoperative complications, postoperative BCVA, and IOP. Presenting BCVA was hand motions or worse in 43/50 eyes (86%). Mean presenting IOP was 25.8 ± 16.2 mmHg. Lens-induced IOP elevation was present in 24/50 eyes (48%), lens-induced glaucoma in 19/50 (38%), and zonular weakness in 18/43 (42%). Surgery was performed in 40/50 eyes (80%). Phacoemulsification was initially attempted in 30/40 eyes (75%), manual small-incision cataract surgery in 5/40 (13%), and pars plana lensectomy with vitrectomy in 5/40 (13%). Intraoperative complications occurred in 14/40 eyes (35%), including posterior capsule rupture in 8/40 (20%); overall, 16/40 eyes (40%) received an in-the-bag IOL. Mean BCVA improved from 2.39 ± 0.58 logMAR preoperatively to 0.68 ± 0.81 logMAR at the last follow-up (paired analysis; P < 0.001), with 20/40 eyes (50%) achieving 20/40 or better. Mean IOP decreased from 26.0 ± 16.9 mmHg at presentation to 16.7 ± 5.5 mmHg at postoperative month 1 (P = 0.003), although 20/40 eyes (50%) remained on IOP-lowering medications. Morgagnian cataracts were associated with profound visual loss, pressure-related complications, and zonular weakness, with substantial intraoperative risk. Despite this complexity, half of the operated eyes achieved BCVA of 20/40 or better. IOP decreased after cataract extraction in the setting of continued medical therapy in many eyes. These findings support careful preoperative assessment, counseling regarding capsular and zonular complications and potential alternative IOL fixation, and an individualized surgical strategy. However, the retrospective design, modest sample size, and variable follow-up limit interpretation, while the tertiary referral setting may limit generalizability.